Dr majid fotuhi biography of abraham
•
Unravelling the connection between COVID and Alzheimer’s disease: a comprehensive review
1 Introduction
The World Health Organisation (WHO) recorded more than million fatalities as of June 26, , and there were more than million confirmed COVID infections worldwide (Crook et al., ). In December , an outbreak of pneumonia with an unknown origin was initially reported in Wuhan, Hubei Province, China (Sharma, ). Angiotensin-converting enzyme 2 (ACE-2) receptors are a route by which the virus that causes COVID, severe acute respiratory syndrome coronavirus 2 (SARSCoV-2), enters cells (Kumar et al., ). SARS-CoV-2 is a positive-strand RNA virus that is exceedingly contagious and calls for exceptional care to stop transmission (Sharma, ). Once inside the body, the virus replicates and matures, causing an inflammatory response in some patients, including the activation and infiltration of immune cells by various cytokines (Crook et al., ). The ACE-2 receptor is present in many cell types t
•
Expert Speakers
Walter Greenleaf, PhD fryst vatten a research neuroscientist and medical product developer working at Stanford University. Walter is known internationally as an early pioneer in digital medicin and virtual environment technology. With over three decades of research and product development experience in the field of medical virtual reality technology, Walter fryst vatten considered a leading authority in the field.
As a scientist and medical product developer, Walter’s focus has been on computer-supported clinical products, with a specific focus on virtual reality and digital health technology to treat Post-traumatic Stress Disorder, Anxiety Disorders, Traumatic Brain Injury and Stroke, Addictions, Autism, and other difficult problems in behavioral and physical medicine. He has founded and managed several medical product companies, including Pear Therapeutics, Virtually Better, InWorld Solutions, Cognitive Leap, and Greenleaf Medical.
Walter recently served as the Director for the
•
Recent progress in neurodegenerative diseases and gliomas
Curator: Larry H. Bernstein, MD, FCAP
LPBI
Alzheimer’s Protein Not All Bad, Says MassGen Study
A controversial idea—that amyloid-beta (Aβ) protein fights bacterial infections in the brain—has gained additional support from a new study. Previously, the idea seemed worthy of investigation, if a bit of a stretch, on the basis of cell culture results. Now, thanks to the efforts of a scientific team lead by researchers based at Massachusetts General Hospital, it has been reinforced by observations of how the Aβ protein functions in animals’ brains.
Details of the new study appeared May 25 in the journal Science Translational Medicine, in an article entitled, “Amyloid-β Peptide Protects against Microbial Infection in Mouse and Worm Models of Alzheimer’s Disease.” The article suggests that the tendency of Aβ protein to form insoluble aggregates is not, as has been widely assumed, intrinsically abnormal, even